Yuchen Jiaye

Beijing Yuchen Jiaye Biotechnology is a clinical-stage Chinese biotechnology company dedicated to the development of next-generation immune cell therapies. The company leverages a proprietary platform for the large-scale expansion and activation of Natural Killer (NK) cells to treat advanced solid tumors. Their primary focus is on developing off-the-shelf allogeneic NK cell products that can be administered without the need for patient-specific HLA matching. Yuchen Jiaye's pipeline includes candidates targeting hepatocellular carcinoma and other refractory malignancies, currently progressing through early-phase clinical trials. The company's technology aims to overcome the limitations of current CAR-T therapies in solid tumor environments by utilizing the innate killing capabilities of NK cells.